Compare Sana Biotechnology Inc (SANA) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Sana Biotechnology Inc trades at $3.24 (market cap $1.03B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $61.24. The key difference: Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | VWO | |
|---|---|---|
Market Cap | $1.03B | — |
Sector | Health | — |
52-Week High | $5.92 | $61.44 |
52-Week Low | $2.68 | $52.42 |
Enterprise Value | $946.04M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
VWO trades at $61.245, down 0.32% on the day, with a bullish technical signal driven by moving averages. The ETF shows strong institutional accumulation, with multiple firms increasing stakes recently. News highlights robust emerging markets performance and record capital inflows, though expense ratios and China exposure remain focal points for investors.
The outlook for VWO is positive given institutional buying and favorable EM trends, but risks include currency volatility and concentrated country weights. Upside hinges on sustained EM outperformance versus developed markets, while any China downturn could pressure returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
